Skip to main content

Table 2 Clinical demographics of the ISR and non-ISR groups in this study

From: Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case–control study

Parameter Total
(N = 93)
ISR
(N = 45)
Non-ISR
(N = 48)
p value
Age (years) 65.71 ± 8.73 65.69 ± 8.82 65.61 ± 8.72 0.12
Gender
   Male 76 (81.72%) 41 (91.11%) 35 (72.92%)
   Female 17 (18.28%) 4 (8.89%) 13 (27.08%)
Smoking 3 (3.23%) 2 (4.44%) 1 (2.08%)
Comorbidities
   Hyperlipidemia 84 (90.32%) 42 (93.33%) 42 (87.50%) 0.34
   Hypertension 71 (76.34%) 33 (73.33%) 38 (79.17%) 0.51
   Angina pectoris 42 (45.16%) 22 (48.89%) 20 (41.67%)
   Diabetes 29 (31.18%) 15 (33.33%) 14 (29.17%) 0.67
   Chronic CHF 5 (5.38%) 3 (6.67%) 2 (4.17%)
Medications
   Aspirin 75 (80.65%) 40 (88.89%) 35 (72.92%) 0.05
   Beta blocker 51 (54.84%) 29 (64.44%) 22 (45.83%) 0.07
   CCBs 30 (32.26%) 14 (31.11%) 16 (33.33%) 0.82
   ARB 61 (65.59%) 30 (66.67%) 31 (64.58%) 0.83
   Clopidogrel 43 (46.24%) 15 (33.33%) 28 (58.33%) 0.02
   Lipid-lowering agent 84 (90.32%) 41 (91.11%) 43 (89.58%) 0.80
  1. Data are presented as the mean ± standard deviation or number (percentage). CHF, cardiac heart failure; CCBs, calcium channel blockers; ARB, angiotensin II receptor blocker